Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy
The Phase II/III RAMIRIS STUDY

Ramucirumab (Cyramza®), Irinotecan, Folinsäure, 5-Fluorouracil (5-FU)

Status: Rekrutierung beendet

Klinische Settings

Beteiligte

Identifier

Links

Publikationen

Kontakt